Mild to moderate chronic hypertension could be managed expectantly up to 41 weeks if SPE did not develop.

no Variant position Variant Count Amino Acid Change Mutation Types c.8343c>G 37 D2781E missense c.8360g>R 34 R2787[H,R] missense c.6073g>K 32 G2025[G,*] nonsense c.8397g>R 27 NC silent c.1360a>R 25 T454A missense c.5883c>M 25 H1961Q missense c.8084a>R 25 N2695[N,S] missense c.6498t>Y 24 NC silent c.7956a>G 24 0, E2652[D] missense c.8143t>Y 24 S2715[P,S] missense c.8170g>A 24 A2724[T,A] missense c.8208a>R 24 NC silent c.8399a>M 24 Y2800S missense c.8060a>M 23 Y2687S missense c.8265g>C 23 NC silent c.8297g>R 23 R2766H missense c.8260t>Y 22 W2754R missense c.1432c>Y 21 P478S missense c.4126a>R 21 R1376G missense c.8192c>G 21 T2731R missense c.8201a>R 21 H2734R missense c.10307g>S 21 G3436A missense c.5541g>R 20 T1847[H,R] missense c.6580t>Y 20 Y2194H missense c.8312a>R 20 Q2771R missense c.1330g>R 18 G444R missense c.4079g>R 18 R1360H missense c.5051g>R 18 R1684H missense c.9645g>K 18 NC silent c.995g>K 17 G332V missense c.7962t>Y 17 H2654[T,M] missense c.8251t>K 17 S2751[A,S] missense c.8301t>Y 17 NC silent c.8332g>A 17 A2778[T,A] missense c.8382a>W 17 R2794[R,S] missense c.10194t>Y 17 NC silent c.5095c>Y 16 R1699C missense

No abstract

Background: As COVID-19 has neither a standard treatment protocol nor guidelines, there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulations for severe COVID-19 pneumonia patients. This study aimed to assess the most suitable modality in this high-risk group. Methods: A prospective, experimental study design was adopted that included 123 severe COVID-19 pneumonia patients admitted at Assiut University Hospital. Patients were divided into three groups according to a combined corticosteroid and anticoagulants therapy protocol. Group A included 32 patients, group B included 45 patients, and group C included 46 patients. Assessment of cases was conducted according to the treatment type and duration, weaning duration from oxygen therapy, length of hospital and ICU stay, and complications during treatment. Three months follow-up after discharge was performed. Results: the three patient groups showed significant differences regarding the 3-month outcome, whereas Group C showed the highest cure rate, lowest lung fibrosis, and lowest mortality rate over the other two groups. The in-hospital outcome, the development of pulmonary embolism, bleeding, hematoma, acute kidney disease, and myocardial infarction showed a significant difference between groups (p values < 0.05). Mortality predictors among severe COVID-19 patients by multivariable Cox hazard regression included treatment modality, history of comorbid diseases, increased C reactive protein, high neutrophil-lymphocyte ratio, and shorter ICU and hospital stay. Conclusion: the use of combined methylprednisolone and therapeutic Enoxaparin, according to a flexible protocol for COVID-19 patients with severe pneumonia, had two benefits; the prevention of disease complications and improved clinical outcome.